Sun Pharmaceutical Industries Limited has announced the appointment of Dr. Andreas Eugen Busch to its Board of Directors, effective 12 May 2026. Dr. Busch, a distinguished expert in drug discovery and innovation, joins the Board for a five-year term. Concurrently, the company announced that Ms. Rama Bijapurkar will retire from the Board on 20 May 2026, with Ms. Satyavati Berera stepping in to serve on the Audit and Risk Management Committees.
Strengthening Board Expertise in Innovation
The appointment of Dr. Andreas Eugen Busch marks a strategic enhancement of the company’s leadership capabilities. As the current Chief Innovation Officer of Absci, Dr. Busch brings extensive global experience in research and development. His career includes leadership roles at industry giants such as Sanofi, Bayer, and Shire, having contributed to the journey of over 15 commercial drugs from the laboratory bench to FDA approval.
Academic and Professional Background
In addition to his corporate roles, Dr. Busch serves as an Extraordinary Professor of Pharmacology at the Johann Wolfgang Goethe-University in Frankfurt, Germany. He holds a PhD in Pharmacology from the same institution. His deep technical expertise is expected to provide significant value to the company’s ongoing efforts in drug discovery and late-stage clinical development.
Changes in Committee Composition
Following the planned retirement of Ms. Rama Bijapurkar on 20 May 2026, the company has streamlined its committee structure. To ensure continuity and governance excellence, the Board has appointed Ms. Satyavati Berera to the Audit Committee and the Risk Management Committee, effective 12 May 2026.
Source: BSE
